Novel Therapies for Sleep Apnea-The Implants Have Arrived!

Positive airway pressure (PAP) therapy has been the standard treatment of choice for sleep disordered breathing, with 29-83% of patients being noncompliant. With the advent of newly Food and Drug Adminisatration (FDA)-approved implantable stimulators for treating sleep disordered breathing in a fraction of noncompliant PAP therapy patients, the landscape of sleep medicine and sleep technology is changing to narrow the gap between compliant and non-compliant patients. The remedē® System for treating central sleep apnea and the Inspire® upper airway stimulation (UAS) therapy for treating obstructive sleep apnea are providing new tools for sleep physicians, elevating sleep technologists' expertise, and paving the way for personalized medicine.